Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Amplify Weight Loss Drug & Treatment ETF THNR
Morningstar’s Analysis THNR
Will THNR outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 59.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.19 | 578,375 | Healthcare |
Novo Nordisk AS ADR | 8.45 | 480,029 | Healthcare |
CSPC Pharmaceutical Group Ltd | 5.92 | 336,229 | Healthcare |
Amgen Inc | 5.65 | 320,929 | Healthcare |
Pfizer Inc | 5.40 | 306,396 | Healthcare |
Innovent Biologics Inc | 5.39 | 306,139 | Healthcare |
AstraZeneca PLC | 5.24 | 297,738 | Healthcare |
Roche Holding AG Ordinary Shares new | 4.66 | 264,664 | Healthcare |
AbbVie Inc | 4.61 | 261,750 | Healthcare |
Merck & Co Inc | 4.58 | 260,152 | Healthcare |